Your browser doesn't support javascript.
loading
Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
Jathal, Maitreyee K; Steele, Thomas M; Siddiqui, Salma; Mooso, Benjamin A; D'Abronzo, Leandro S; Drake, Christiana M; Whang, Young E; Ghosh, Paramita M.
Afiliación
  • Jathal MK; Department of Urology, University of California Davis, Sacramento, CA, United States.
  • Steele TM; Department of Urology, University of California Davis, Sacramento, CA, United States.
  • Siddiqui S; VA Northern California Health Care System, Mather, CA, United States.
  • Mooso BA; VA Northern California Health Care System, Mather, CA, United States.
  • D'Abronzo LS; Department of Urology, University of California Davis, Sacramento, CA, United States.
  • Drake CM; Department of Statistics, University of California Davis, Davis, CA, United States.
  • Whang YE; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States.
  • Ghosh PM; Department of Urology, University of California Davis, Sacramento, CA, United States. paghosh@ucdavis.edu.
Br J Cancer ; 121(3): 237-248, 2019 07.
Article en En | MEDLINE | ID: mdl-31209328

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor ErbB-2 / Quinazolinonas / Neoplasias de la Próstata Resistentes a la Castración / Lapatinib Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Br J Cancer Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor ErbB-2 / Quinazolinonas / Neoplasias de la Próstata Resistentes a la Castración / Lapatinib Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Br J Cancer Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos